Therefore, the combination of anti-VEGF-A (bevacizumab; humanized IgG1, Roche) and anti-CTLA-4 (ipilimumab) was investigated in a phase I trial in advanced melanoma patients. This evidence concerns the gene VEGFA and melanoma.